Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus FULVICIN U F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus FULVICIN U F.
EXTINA vs FULVICIN-U/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Category C
Category C
Antifungal
Antifungal